Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia, Zoey Becker, or Will Maddox and it will be featured here at the end of each week.
Legend Biotech CEO departs without successor in place
Legend Biotech
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on founding CEO Fangliang Zhang, Ph.D.
Legend’s board appointed Carvykti President Alan Bash to fill Huang’s shoes until a permanent successor can be named. Bash joined the company in 2024 and has been managing the Johnson & Johnson-partnered multiple myeloma CAR-T therapy, which is the lead drug in Legend’s portfolio.
Legend’s SEC filing said that Huang’s resignation “was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices or the Company’s financial statements or internal controls over financial reporting.” Huang will remain as an advisor through August to support the transition. Story
Sarepta snags Severino as new CEO
Sarepta Therapeutics
Michael Severino, M.D., is the successor to Sarepta Therapeutics CEO Doug Ingram, effective this past Tuesday, July 28th. Severino hails most immediately from Flagship Pioneering’s Tessera Therapeutics, where he served as CEO for the past four years. At Tessera, Severino helped to advance its first in vivo gene-editing therapy, TSRA-196, now being co-developed and commercialized with Regeneron, into the clinic.
Prior to Tessera, he served as vice chairman and president at North Chicago-based AbbVie. Here he helped steer R&D efforts for numerous drugs including Rinvoq, Skyrizi, and Venclexta. Under his leadership, AbbVie built leading franchises in hematologic oncology, immunology, and neuroscience.
“It is a privilege to join Sarepta, the leader in precision genetic medicine for rare diseases, and a company driven by an extraordinary purpose: bringing innovative therapies, hope and possibility to patients and families facing serious and life-threatening diseases,” Severino said.
He also held leadership roles at both Merck and Amgen, where he logged a total of more than 15 years, before his tenure at AbbVie. Story.
Nasus sniffs out new CEO in former Teva exec
Nasus Pharma
Israel-based Nasus Pharma is swapping out its CEO Dan Teleman with an experienced exec who previously worked in leadership roles at another major Israeli pharma. Succeeding Teleman, Brendan O’Grady joins Nasus as CEO following a stint as the chief executive at Assertio Holdings, which was bought out by Zydus Pharma earlier this year.
Before that, O’Grady spent 21 years at Teva Pharmaceuticals in roles of increasing responsibility, culminating as president and CEO of Teva’s U.S. business. At Nasus, the executive is expected to bring “strategic vision, extensive experience in payors and reimbursement, and proven commercial leadership,” board chair Udi Gilboa explained.
O’Grady will be tasked with leading Nasus’ next phase of growth and stirring up the maximum commercial potential of its Nasax intranasal technology platform and lead candidate NS002, an epinephrine treatment for type 1 allergic reactions. The asset could address a “significant unmet need” and make for a “growing $2 billion market opportunity,” O’Grady commented. Release
> Amgen vet Debra Jeske Zack, M.D., Ph.D., is bringing her 25 years of experience in drug development for immune-mediated diseases to Spero Therapeutics as its new chief medical officer. Release
> 37 years after joining Ionis Pharmaceuticals as a founding scientist, chief scientific officer Frank Bennett, Ph.D., is set to hang up the gloves in February 2027, with research head Eric Swayze, Ph.D., taking on his responsibilities. Release
> Spruce Biosciences is branching out with the appointment of experienced executive Adrian Quartel, M.D., as its new chief medical officer. Release
> In vivo CAR T-cell company Liberate Bio appointed BMS and Regeneron alum Steven Bernstein, M.D., as new CMO to help bring their leading in vivo CAR-T program to the clinic. Release.
> Machine learning and AI-focused Recursion welcomed 15-year Microsoft veteran Hoifung Poon, Ph.D., as first Chief AI Officer. Linkedin.
> Boston-based psychedelic therapeutics company Rose Hill tapped former Takeda and Deciphera regulatory strategy expert Jama Pitman as new CEO to advance their psilocybin drug pipeline. Release.
> Ashlins Pharmaceuticals has named Andres Gutierrez, Ph.D., as its new chief medical officer. He brings more than two decades of experience in oncology, including senior roles at Ayala Pharmaceuticals, Oncolytics Biotech, Bristol Myers Squibb and more. LinkedIn
> Terence Rooney, M.D., has been appointed chief medical officer of Kymera Therapeutics, a clinical-stage immunology biotech. He succeeds Jared Gollob, M.D., who will retire after eight years and remain as an advisor through the end of the year. Release
> Secretome Therapeutics has named Teji Singh, M.D., as chief medical officer and transitioned Marshelle Smith, M.D., to the role of chief development officer. Singh most recently led clinical development at Sarepta Therapeutics. Release
> Linda Shapiro Manning, M.D., Ph.D., has been named the new chief medical officer of Ambrosia Biosciences. She brings more than 30 years of leadership experience in obesity and cardiometabolic disease at Novo Nordisk, Boehringer Ingelheim and Rhythm Pharmaceuticals. Release
Facts Only
* Ying Huang, Ph.D., left Legend Biotech suddenly without a successor.
* Alan Bash was appointed President to fill the CEO role at Legend Biotech until a permanent successor is named; he joined in 2024.
* Alan Bash manages Johnson & Johnson-partnered multiple myeloma CAR-T therapy at Legend Biotech.
* Michael Severino, M.D., succeeded Doug Ingram as CEO of Sarepta Therapeutics on July 28th.
* Michael Severino previously served as CEO of Tessera Therapeutics and held leadership roles at AbbVie, Merck, and Amgen.
* Brendan O’Grady succeeded Dan Teleman as CEO of Nasus Pharma.
* Brendan O’Grady previously served as CEO of Assertio Holdings and held a role at Teva Pharmaceuticals.
* Debra Jeske Zack, M.D., Ph.D., was appointed Chief Medical Officer for Spero Therapeutics.
* Frank Bennett, Ph.D., will retire from Ionis Pharmaceuticals in February 2027.
* Adrian Quartel, M.D., was appointed Chief Medical Officer for Spruce Biosciences.
* Steven Bernstein, M.D., was appointed CMO for Liberate Bio.
* Hoifung Poon, Ph.D., was appointed Chief AI Officer at Recursion.
* Jama Pitman was appointed CEO of Rose Hill.
* Andres Gutierrez, Ph.D., was named Chief Medical Officer for Ashlins Pharmaceuticals.
* Terence Rooney, M.D., was appointed Chief Medical Officer of Kymera Therapeutics.
* Teji Singh, M.D., was named Chief Medical Officer for Secretome Therapeutics.
* Linda Shapiro Manning, M.D., Ph.D., was named Chief Medical Officer of Ambrosia Biosciences.
Executive Summary
Full Take
The consistent theme across these executive changes involves the rapid movement of leadership and the leveraging of deep industry experience in highly specialized biopharma and technology sectors. The transitions at Legend Biotech underscore challenges related to succession planning, particularly when departures are sudden, even if officially attributed to no disagreement over operations. The pattern observed across Sarepta, Nasus, and other entities is a strategic infusion of leadership with specific domain expertise—such as gene editing, oncology pipelines, payor/reimbursement strategy, and deep scientific background from major pharmaceutical players. This suggests that the market values immediate, proven operational continuity anchored by individuals who understand complex regulatory and commercial landscapes.
The shift in focus from internal succession (Legend Biotech) to external executive recruitment highlights a dynamic where institutional stability is immediately addressed through external talent acquisition. The pattern of experienced executives moving between companies with overlapping therapeutic focuses (e.g., Severino’s movement across gene editing, oncology, and immunology firms) points toward an ecosystem where specialized knowledge is highly portable and demanded by innovation cycles. The implication is that successful navigation in this industry relies less on long-term internal planning during volatility and more on quickly onboarding leaders who bring immediate, relevant strategic vision and commercial leadership to execute specific growth mandates, such as advancing platform technologies or addressing significant unmet medical needs demonstrated by specialized pipeline assets.
What framework governs the valuation of these transitions—is it purely about operational continuity, or is it a reflection of investor appetite for specific therapeutic modalities? How does this constant reshuffling affect the long-term institutional memory within these companies? Furthermore, if specialization drives hiring, what happens to the holistic, cross-disciplinary leadership required for managing complex, multi-faceted biotech ventures?
Sentinel — Human
This text appears to be a compilation of factual updates from various industry sources, framed within a specific newsletter format, exhibiting characteristics consistent with human-curated journalistic output rather than pure synthetic generation.